Rui Avelar Sells 2,261 Shares of Evolus (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS) insider Rui Avelar sold 2,261 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total transaction of $16,166.15. Following the completion of the sale, the insider owned 356,821 shares in the company, valued at approximately $2,551,270.15. The trade was a 0.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Evolus Trading Up 0.2%

Shares of Evolus stock opened at $6.67 on Wednesday. The firm’s 50 day moving average is $6.91 and its 200 day moving average is $7.46. The firm has a market capitalization of $432.35 million, a PE ratio of -7.25 and a beta of 0.87. Evolus, Inc. has a 1 year low of $5.71 and a 1 year high of $17.12.

Evolus (NASDAQ:EOLS) last issued its earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. The firm had revenue of $68.97 million for the quarter, compared to analyst estimates of $91.23 million. Evolus had a negative net margin of 20.49% and a negative return on equity of 759.04%. As a group, research analysts anticipate that Evolus, Inc. will post -0.61 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC increased its position in shares of Evolus by 33.2% during the third quarter. Nantahala Capital Management LLC now owns 5,726,857 shares of the company’s stock worth $35,163,000 after buying an additional 1,428,931 shares during the period. Caligan Partners LP lifted its holdings in Evolus by 23.8% in the third quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock valued at $25,413,000 after buying an additional 796,973 shares during the period. Vanguard Group Inc. boosted its position in Evolus by 3.3% during the third quarter. Vanguard Group Inc. now owns 3,428,943 shares of the company’s stock valued at $21,054,000 after acquiring an additional 110,693 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in Evolus during the 2nd quarter worth about $22,431,000. Finally, Soleus Capital Management L.P. grew its holdings in Evolus by 96.4% during the 2nd quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock worth $19,516,000 after acquiring an additional 1,039,842 shares during the period. Institutional investors own 90.69% of the company’s stock.

Analyst Upgrades and Downgrades

EOLS has been the subject of a number of recent research reports. Wall Street Zen raised Evolus from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Evolus in a research note on Wednesday, December 24th. BTIG Research reiterated a “buy” rating and issued a $18.00 price objective on shares of Evolus in a report on Monday, September 8th. Mizuho reduced their target price on shares of Evolus from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Monday, December 1st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $20.80.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.